Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

Sakabe, Koichi; Fukuda, Nobuo; Wakayama, Katsunori; Nada, Teru; Shinohara, Hisanori; Tamura, Yoshiyuki

doi:10.1016/j.amjcard.2004.04.067

Cited by 36 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26,27 In this study, PAI-1 antigen and activity fell in all treatment groups; ORIGINAL ARTICLE however, only subjects in the 8RS group had a significant decrease in PAI-1 antigen from baseline, and no treatment effect was observed. This raises doubts as to whether TZDs have any further effects beyond statins in reducing PAI-1 antigen production and activation in patients with T2DM.…”

Section: Discussionmentioning

confidence: 78%

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Murdoch

Parikh

et al. 2006

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease (CVD). In some cases, sdLDL persists after treatment with a statin to reduce levels of LDL. The effect of the addition of a thiazolidinedione, rosiglitazone (RSG) (4 mg/day or 8 mg/day) to statin therapy on LDL phenotype and C reactive protein (CRP) levels was investigated in a 12-week, placebo-controlled study of 72 T2DM patients who were well controlled and on a statin, but who had persistently predominant sdLDL.Addition of RSG 8 mg to statin therapy significantly increased LDL buoyancy (relative flotation +0.014, p=0.003) and LDL particle size (+4.2Å, p=0.001) from baseline and relative to the change with placebo (+0.014 and +3.8Å; p=0.03 and p=0.04, respectively), and was associated with a non-significant decrease in sdLDL. RSG 8 mg moderately, but significantly, increased total cholesterol (by 12.2%, p=0.004), LDL-cholesterol (11.2%, p=0.02) and intermediate-density lipoprotein (IDL)-cholesterol from baseline but did not increase total or LDL apolipoprotein B. RSG 4 mg and 8 mg significantly reduced CRP compared with placebo (-44.9% and -48.0%; p=0.008 and p=0.004, respectively), and significantly reduced insulin resistance and fasting plasma glucose from baseline.Addition of RSG to statin therapy may further reduce cardiovascular risk by improving the LDL phenotype, as well as reducing insulin resistance and CRP levels. However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone. 2006;3:189-96 Diabetes Vasc Dis Res

show abstract

Section: Discussionmentioning

confidence: 78%

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Murdoch

Parikh

et al. 2006

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

show abstract

“…Although the therapeutically beneficial effects of statins in these diseases are generally attributed to their cholesterol-lowering action, the results from an increasing number of in vitro and in vivo studies indicate that statins also have anti-inflammatory effects that are independent of their hypocholesterolemic activity [2,3]. Statins have also been reported to have immunomodulatory, antioxidative, and antithrombotic actions [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Enrollment criteria included a low-density lipoprotein (LDL) cholesterol concentration N160 mg/dl and a triglyceride concentration b400 mg/dl while following the diet therapy [2,3]. Patients who smoked or had diabetes, hypertension, vascular events, revascularization procedures, coronary artery disease, or active liver disease, or took any concomitant drug, were excluded [2,3].…”

Section: Methodsmentioning

confidence: 99%

Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function

Sakabe

Fukuda

et al. 2008

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

Cited by 36 publications

References 20 publications

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients

Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function

Contact Info

Product

Resources

About